

THE ELDER CARE MARKET: PRODUCTS AND SERVICES



HLC062B
January 2014

Peggy Lehr
Project Analyst

ISBN: 1-56965-664-9

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
INFORMATION SOURCES	3
ANALYST CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
EMPHASIS OF THE REPORT	6
HEALTHCARE	6
HOUSING	7
ASSISTIVE TECHNOLOGY	7
<i>SUMMARY TABLE PROJECTED NEEDS OF THE U.S. ELDERLY, THROUGH 2018 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE PROJECTED NEEDS OF THE ELDERLY BY TYPE OF NEED, 2013 AND 2018 (%)</i>	9
CHAPTER 3 OVERVIEW OF GLOBAL ELDERLY POPULATION	11
DEFINITIONS	11
TRENDS IN GLOBAL AGING	11
HEALTHCARE AND AGING	11
HOUSING AND AGING	12
THE GLOBAL ENVIRONMENT FOR THE ELDERLY	12
GLOBAL SOCIAL ENVIRONMENT	12
Intergenerational Living Issues in Developing Countries	13
Intergenerational Living Issues in Developed Countries	13
GLOBAL HOUSING REALITY FOR THE ELDERLY	13
Europe	13
China	13
GLOBAL ECONOMIC REALITY FOR THE ELDERLY	14
Economic Trends for Elderly Outside the U.S.	14
Europe	14
India	14
Japan	15
Economic Trends for U.S. Elderly	15
GLOBAL DEMOGRAPHIC TRENDS, BY COUNTRY	15
<i>TABLE 1 PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES, 2012 (MILLIONS/%)</i>	15
THE ELDERLY IN THE U.S.	16
DEMOGRAPHICS IN THE U.S.	16
<i>TABLE 2 ELDERLY POPULATIONS COMPARED WITH OVERALL POPULATIONS BY STATE, 2009</i>	16

TOPIC	PAGE NO.
<i>TABLE 3 U.S. ELDERLY POPULATION, BY STATE, AS A PERCENTAGE OF THE OVERALL STATE POPULATION, 2010 (%)</i>	18
HEALTH OF THE U.S. ELDERLY	19
U.S. Health Trends	19
Discrepancies in Minority Health Status	19
Elderly Living with Chronic Health Conditions	20
SHIFTING DEMOGRAPHICS IN THE U.S.	20
Racial and Ethnic Changes	20
<i>FIGURE 1 U.S. POPULATION OVER 65 BY RACE, 2010 (%)</i>	20
GOVERNMENT LEGISLATION AND PROGRAMS AIMED AT THE ELDERLY	21
THE AMERICANS WITH DISABILITIES ACT	21
ADA and Employee Rights	22
THE TELECOMMUNICATIONS ACT OF 1934	22
THE FAIR HOUSING ACT	22
AIR CARRIER ACCESS ACT	23
VOTING ACCESSIBILITY FOR THE ELDERLY AND HANDICAPPED ACT OF 1984	23
ARCHITECTURAL BARRIERS ACT OF 1968	23
MEDICAL DEVICE LEGISLATION	23
THE AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009	24
U.S. GOVERNMENT SPONSORED NUTRITION PROGRAMS	24
NON-GOVERNMENTAL NUTRITION PROGRAMS	24
END-OF-LIFE CONSIDERATIONS	25
LEGAL MATTERS	25
CHAPTER 4 INDUSTRY TRENDS BY SECTOR-HEALTHCARE	27
U.S. HEALTHCARE FOR THE ELDERLY	27
<i>TABLE 4 PROJECTED U.S. MARKET FOR ELDERCARE HEALTHCARE MEDICATIONS, PRODUCTS AND SURGICAL PROCEDURES, THROUGH 2018 (\$ MILLIONS)</i>	28
HOSPITALIZATIONS FOR HEALTHCARE PROBLEMS OF THE ELDERLY	28
<i>TABLE 5 NUMBER OF DISCHARGES FROM NONFEDERAL U.S. HOSPITALS FOR INDIVIDUALS 65 OR OLDER, 2010 (THOUSANDS)</i>	28
ARTHRITIS	29
CURRENT TREATMENTS	29
Medications	29
Rheumatoid Arthritis	30
COX2 Inhibitor	30
Disease-modifying Antirheumatic Drugs	30
Biologics to Treat RA	30
Corticosteroids	31
NSAIDs	31
Osteoarthritis	31
THE FUTURE BURDEN OF ARTHRITIS IN THE U.S.	31
<i>FIGURE 2 FUTURE BURDEN OF ARTHRITIS FOR THOSE OVER 65 IN THE U.S. BY GENDER, 2010-2030 (\$ MILLIONS)</i>	31
ARTHRTIS TREATMENT MARKET PROJECTIONS	32
<i>TABLE 6 PROJECTED U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	33
CARDIOVASCULAR DISEASES	33

TOPIC	PAGE NO.
CARDIOVASCULAR DISEASE IN THE U.S.	33
Risk Factors	34
Current Treatments for Heart Disease	34
<i>TABLE 7 SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME AND MANUFACTURER</i>	35
Surgical Options	37
CARDIOVASCULAR TREATMENT MARKET ANALYSIS	37
<i>TABLE 8 U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS AND SURGERY, THROUGH 2018 (\$ MILLIONS)</i>	38
<i>TABLE 9 PROJECTED U.S. MARKET FOR CARDIOVASCULAR DRUGS AND SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	38
CANCER	38
TYPES OF CANCER	39
GLOBAL RISK FACTORS	39
<i>FIGURE 3 ESTIMATED NEW CASES OF CANCER, GLOBALLY, 2008 (%)</i>	39
CANCER RATES IN THE U.S. ELDERLY	40
CANCER TREATMENT MARKET ANALYSIS	41
<i>TABLE 10 LEADING CANCER DRUGS, WITH PRODUCT, MANUFACTURER AND INDICATION, 2012</i>	41
MARKET ANALYSIS FOR U.S. CANCER DRUGS	42
<i>TABLE 11 PROJECTED U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	42
<i>TABLE 12 PROJECTED MARKET FOR CANCER DRUGS FOR U.S. ELDERLY PATIENTS, THROUGH 2018 (\$ MILLIONS)</i>	42
DIABETES	43
TYPE 2 DIABETES INTERNATIONALLY	43
Type 2 Diabetes in Asia	43
PREVALENCE OF TYPE 2 DIABETES IN THE U.S.	44
<i>TABLE 13 PREVALENCE OF DIABETES IN THE U.S., THROUGH 2018 (CASES IN MILLIONS)</i>	44
CURRENT TREATMENT OF DIABETES	44
TYPE 1 DIABETES	44
Insulin	44
Insulin Administration Devices	45
TYPE 2 DIABETES	45
Sulfonylureas	45
<i>TABLE 14 SULFONYLUREAS</i>	46
Biguanides	46
Alpha-Glucosidase Inhibitor	46
Glitazones	47
Prandial Glucose Regulators	47
GLP-1 Analogs/Incretin Mimetics	47
Amylin Mimetic	47
<i>TABLE 15 ORAL HYPOGYCEMICS</i>	48
MONITORING DEVICES FOR DIABETES	48
DIABETES THERAPY MARKET LEADERS	49
DIABETES MARKET ANALYSIS	49
<i>TABLE 16 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND MONITORING PRODUCTS, THROUGH 2018 (\$ MILLIONS)</i>	49

TOPIC	PAGE NO.
<i>TABLE 17 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND MONITORING PRODUCTS FOR THE ELDERLY, THROUGH 2018 (\$ MILLIONS)</i>	50
SENSORY IMPAIRMENTS	50
<i>TABLE 18 PROJECTED U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS, SURGERY AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	50
SPEECH IMPAIRMENT	51
WRITING DIFFICULTY	51
VISION IMPAIRMENT	51
<i>TABLE 19 ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS OVER 40, 2010</i>	52
Macular Degeneration	52
<i>TABLE 20 PROJECTED GLOBAL MARKET FOR PRODUCTS TO TREAT AMD, THROUGH 2018 (\$ MILLIONS)</i>	53
<i>TABLE 21 PROJECTED U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	53
Cataracts	53
<i>TABLE 22 PROJECTED COSTS OF CATARACT SURGERY FOR THE U.S. ELDERLY, THROUGH 2018 (\$ MILLIONS)</i>	54
Glaucoma	54
Ethnic Disparities	54
Glaucoma Prescription Market	55
<i>TABLE 23 PROJECTED U.S. ELDERLY MARKET FOR GLAUCOMA PRESCRIPTION MEDICATIONS, THROUGH 2018 (\$ MILLIONS)</i>	55
Eyewear	55
<i>TABLE 24 PROJECTED U.S. EYEWEAR SALES, THROUGH 2018 (\$ MILLIONS)</i>	56
Market for Eyewear Products for Seniors	56
<i>TABLE 25 PROJECTED U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	56
HEARING IMPAIRMENT	57
Causes of Hearing Loss	57
Market Analysis for Hearing Aid Products	57
<i>TABLE 26 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS, THROUGH 2018 (\$ MILLIONS)</i>	58
<i>TABLE 27 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS FOR THE ELDERLY, THROUGH 2018 (\$ MILLIONS)</i>	58
NEUROLOGICAL DISEASES	58
<i>TABLE 28 PROJECTED MARKET IN THE U.S. FOR DEMENTIA AND DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	59
ALZHEIMER'S DISEASE	59
<i>FIGURE 4 CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%)</i>	60
Economic Burden	60
Current Treatments for Alzheimer's	61
<i>TABLE 29 COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE, 2013</i>	62
Market Analysis for Dementia Costs	62
<i>TABLE 30 PROJECTED MARKET IN THE U.S. FOR DEMENTIA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	63
DEPRESSION	63
Origins of the Disease	63

TOPIC	PAGE NO.
Genetic Factors	63
Biological Factors	64
Sociological Factors	64
Psychological Factors	64
Costs of Depression	64
Market Analysis for Depression in the Elderly	65
<i>TABLE 31 PROJECTED U.S. MARKET FOR DEPRESSION MEDICATIONS FOR THE ELDERLY, THROUGH 2018 (\$ MILLIONS)</i>	65
ORTHOPEDIC	65
<i>TABLE 32 PROJECTED U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND SURGERIES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	66
OSTEOPOROSIS	66
<i>TABLE 33 UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR OSTEOPOROSIS</i>	66
Osteoporosis Medications	67
<i>TABLE 34 OSTEOPOROSIS MEDICATIONS BY TYPE</i>	67
Market Analysis for Osteoporosis Medications	67
<i>TABLE 35 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS, THROUGH 2018 (\$ MILLIONS)</i>	68
<i>TABLE 36 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	68
FALLS AND THE ELDERLY	68
JOINT REPLACEMENT	68
Market Analysis	69
<i>TABLE 37 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY, THROUGH 2018 (\$ MILLIONS)</i>	69
<i>TABLE 38 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	70
Market Leaders	70
<i>FIGURE 5 MARKET LEADERS FOR RECONSTRUCTIVE IMPLANT PRODUCTS (%)</i>	70
RESPIRATORY	71
<i>TABLE 39 PROJECTED U.S. MARKET FOR RESPIRATORY MEDICATIONS AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	71
ALLERGIES	72
Current Treatments for Allergies	72
<i>TABLE 40 CURRENT ALLERGY TREATMENTS</i>	73
Allergy Market Analysis	74
<i>TABLE 41 PROJECTED MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS IN THE U.S., THROUGH 2018 (\$ MILLIONS)</i>	74
<i>TABLE 42 PROJECTED U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	75
ASTHMA	75
Treatments	76
<i>TABLE 43 PROJECTED U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	76
COPD	76
<i>TABLE 44 PROJECTED U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	77
COPD Treatment Options	77
<i>TABLE 45 CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S.</i>	78

TOPIC	PAGE NO.
Emphysema	79
Chronic Bronchitis	79
OXYGEN THERAPY	79
<i>TABLE 46 PROJECTED U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY SUPPLIES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	80
LOSS OF PATENT PROTECTION	80
<i>TABLE 47 MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN 2008-2021</i>	80
OTHER CHRONIC CONDITIONS	81
DENTAL HEALTH	81
UROLOGICAL PROBLEMS	81
Incontinence Medications	81
<i>TABLE 48 PROJECTED U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	82
BENIGN PROSTATIC HYPERPLASIA (BPH)	82
<i>TABLE 49 SELECTED MEDICATIONS FOR BPH</i>	82
<i>TABLE 50 PROJECTED U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	83
OBESITY	83
CHAPTER 5 INDUSTRY TRENDS BY SECTOR-HOUSING	85
UNPAID CAREGIVERS	85
TOLL ON CAREGIVERS	85
LONG-TERM CARE	86
<i>FIGURE 6 PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER 65 (%)</i>	86
U.S. HOUSING FOR ELDERLY	87
MARKET ANALYSIS	87
<i>TABLE 51 PROJECTED U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	88
AT-HOME REMODELING	88
<i>TABLE 52 PROJECTED U.S. MARKET FOR HOME REMODELING FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	89
HOME HEALTHCARE SERVICES	89
<i>TABLE 53 PROJECTED U.S. MARKET FOR HOME HEALTH SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	89
ADULT DAY CENTERS	90
<i>TABLE 54 PROJECTED U.S. MARKET FOR ADULT DAY CARE SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	91
COMPETITIVE LANDSCAPE FOR HOME HEALTHCARE SERVICES	91
HOUSING FOR LOWER INCOME INDIVIDUALS	91
INSTITUTIONAL CARE ALTERNATIVES FOR SENIORS	92
DEMOGRAPHICS OF INDIVIDUALS IN INSTITUTIONAL SETTINGS	92
ASSISTED LIVING, SKILLED NURSING, MEMORY CARE PROVIDERS	93
<i>TABLE 55 PROJECTED U.S. MARKET FOR SENIOR ASSISTED LIVING AND SKILLED NURSING FACILITIES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	93
TOP INDUSTRY PROVIDERS	93
<i>TABLE 56 TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2012</i>	94
<i>FIGURE 7 PERCENT RANKING OF ASSISTED LIVING PROVIDERS BY CAPACITY IN THE U.S., 2012 (%)</i>	94

TOPIC	PAGE NO.
<i>TABLE 57 TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2012</i>	95
<i>FIGURE 8 PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN THE U.S., 2012 (%)</i>	96
<i>TABLE 58 TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2012</i>	97
ASSISTED LIVING	97
NURSING HOMES	97
MEMORY CARE	98
MARKET CONSTRAINTS	98
RESTRICTED SUPPLY OF NURSING BEDS	98
COST CONTAINMENT EFFORTS BY GOVERNMENT PAYERS	99
IMPLICATIONS OF THE AFFORDABLE CARE ACT (ACA)	99
Care Coordination	99
REIMBURSEMENT ISSUES	100
Medicaid Reimbursement	100
LACK OF FINANCIAL RESOURCES BY SENIORS	100
INDUSTRY COMPETITION	100
RETAINING COMPETENT STAFF	101
CREDIT AND MODERNIZATION FOR SKILLED NURSING FACILITIES	101
INDEPENDENT LIVING	101
ACTIVE ADULT COMMUNITIES	102
RECREATIONALLY BASED RETIREMENT COMMUNITIES	102
SENIOR HOUSING MARKET OPPORTUNITIES	103
MEMORY CARE FACILITIES	103
HOME HEALTHCARE	103
U.S. REGIONAL ANALYSIS	103
NEW FACILITY CONSTRUCTION	103
ACQUISITIONS AND MERGERS IN THE ELDERCARE HOUSING INDUSTRY	103
<i>TABLE 59 SELECTED ACQUISITIONS AND MERGERS IN THE ELDERCARE MARKET, 2011 TO 2013 (\$ MILLIONS)</i>	104
CHAPTER 6 INDUSTRY TRENDS, BY SECTOR-ASSISTIVE TECHNOLOGIES	106
PROJECTED ASSISTIVE TECHNOLOGIES MARKET ANALYSIS FOR ELDERS	106
<i>TABLE 60 PROJECTED U.S. ASSISTIVE TECHNOLOGY MARKET FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	106
<i>FIGURE 9 PROJECTED U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS OVER 65, 2013 AND 2018 (%)</i>	107
MEDICAL AND PERSONAL MONITORING AIDS	108
ACTIVITY LOCATION/PERSONAL MONITORING AIDS	108
Activity/Emergency Location Monitors	108
Remote Medical Monitors	108
Market Fragmentation	109
<i>TABLE 61 SELECTED MEDICAL/PERSONAL MONITORING AID MANUFACTURERS</i>	109
MEDICAL/PERSONAL MONITORING AIDS MARKET GROWTH	109
<i>TABLE 62 PROJECTED U.S. SALES OF MEDICAL/PERSONAL MONITORING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	110
MARKET DRIVERS FOR MEDICAL AND PERSONAL MONITORING AIDS	110
ACCESS AIDS	110
HOME ELEVATORS	110

TOPIC	PAGE NO.
WHEELCHAIR LIFTS	110
STAIR CLIMBERS	111
ACCESSIBLE BATHS AND SHOWERS	111
TRANSFER LIFTS	111
DOOR OPENERS	111
ACCESS AIDS MANUFACTURERS	111
<i>TABLE 63 ACCESS AIDS MANUFACTURERS</i>	112
DAILY LIVING AIDS	112
<i>TABLE 64 SELECTED MANUFACTURERS OF DAILY LIVING AIDS</i>	113
PROJECTED MARKET FOR DAILY LIVING AIDS FOR SENIORS	113
<i>TABLE 65 PROJECTED MARKET FOR DAILY LIVING AIDS FOR SENIORS, THROUGH 2018 (\$ MILLIONS)</i>	113
MOBILITY AIDS	114
<i>TABLE 66 PROJECTED U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	114
WHEELCHAIRS, SCOOTERS AND ACCESSORIES	114
Wheelchairs	114
<i>TABLE 67 WHEELCHAIR MANUFACTURERS</i>	115
Scoters	116
<i>TABLE 68 SCOOTER MANUFACTURERS</i>	116
AMBULATORY AIDS	116
<i>TABLE 69 PROJECTED U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	117
<i>TABLE 70 AMBULATORY AID MANUFACTURERS</i>	117
MOTOR VEHICLE MODIFICATIONS	117
<i>TABLE 71 PROJECTED U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	118
<i>TABLE 72 VEHICLE ASSESS CONVERSION KIT MANUFACTURERS</i>	118
NAVIGATION AIDS	118
<i>TABLE 73 PROJECTED U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	119
OTHER AIDS	119
<i>TABLE 74 PROJECTED U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)</i>	119
BEDS	120
ERGONOMIC AIDS	120
COMMUNICATION AIDS	120
<i>TABLE 75 PROJECTED U.S. ELDERLY MARKET FOR COMMUNICATION AIDS, THROUGH 2018 (\$ MILLIONS)</i>	120
Speech Aids	121
Writing Aids/Computer Access	121
Input Devices	121
Output Devices	121
Software Products	121
Telephony Accessories	122
Text Telephones	122
Amplified Telephones	122
Vision/Reading Aids	122

TOPIC	PAGE NO.
CHAPTER 7 DEVELOPMENTAL PIPELINE FOR ELDERCARE PHARMACEUTICALS	124
TABLE 76 MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS, 2012	124
CANCER	124
BREAST	124
TABLE 77 MAJOR PRODUCT PIPELINES FOR BREAST CANCER	125
COLORECTAL CANCER	125
TABLE 78 MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER	126
DIABETES	126
TABLE 79 MAJOR PRODUCT PIPELINES FOR DIABETES	126
HEART DISEASE/STROKE	128
TABLE 80 MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE	128
KIDNEY DISEASE	128
TABLE 81 MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE	128
MUSCULOSKELETAL	129
OSTEOARTHRITIS	129
TABLE 82 MAJOR PRODUCT PIPELINES FOR OSTEOARTHRITIS	129
OSTEOPOROSIS	129
TABLE 83 MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS	129
Pain	130
TABLE 84 MAJOR PRODUCT PIPELINES FOR PAIN	130
Rheumatoid Arthritis	130
TABLE 85 MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS	131
NEUROLOGICAL	131
DEPRESSION PRODUCT PIPELINE	131
TABLE 86 MAJOR PRODUCT PIPELINES FOR DEPRESSION	132
DEMENCIA PRODUCT PIPELINE	132
TABLE 87 MAJOR PRODUCT PIPELINE FOR DEMENCIA PHARMACEUTICALS	133
RESPIRATORY	133
ASTHMA	133
TABLE 88 MAJOR PRODUCT PIPELINES FOR ASTHMA	133
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)	134
TABLE 89 MAJOR PRODUCT PIPELINES FOR COPD	134
CHAPTER 8 COMPANY DIRECTORY	136
PHARMACEUTICALS	136
ABBOTT LABORATORIES	136
Business Overview	136
Products	136
ASTRAZENECA PLC	137
Business Overview	137
Products	137
BRISTOL-MYERS SQUIBB	137
Business Overview	137
Products	137
CENTOCOR	138
Business Overview	138
Products	138

TOPIC	PAGE NO.
COVIDIEN	138
Business Overview	138
Products	138
DJO GLOBAL, INC.	138
Business Overview	139
Products	139
ELI LILLY	139
Business Overview	139
Products	139
ENDO PHARMACEUTICALS, INC.	139
Business Overview	139
Products	140
FOREST PHARMACEUTICALS	140
Business Overview	140
Products	140
GLAXOSMITHKLINE PLC	140
Business Overview	140
Products	140
JANSSEN PHARMACEUTICALS, INC.	141
Business Overview	141
Products	141
JOHNSON & JOHNSON	141
Business Overview	141
Products	141
MERCK	142
Business Overview	142
Products	142
NOVARTIS INTERNATIONAL AG	142
Business Overview	142
Products	142
NOVO NORDISK	143
Business Overview	143
Products	143
PFIZER	143
Business Overview	143
Products	143
PURDUE PHARMACEUTICALS LP	144
Business Overview	144
Products	144
ROCHE PHARMACEUTICALS	144
Business Overview	144
Products	144
SANOFI-AVENTIS	145
Business Overview	145
Products	145
SERVIER LABORATORIES, LTD	145
Business Overview	145

TOPIC	PAGE NO.
Products	145
TAKEDA PHARMACUETICALS	146
Business Overview	146
Products	146
VECTURA GROUP PLC	146
Business Overview	146
MEDICAL DEVICES	146
BOSTON SCIENTIFIC	146
Business Overview	147
Products	147
MEDTRONIC, INC.	147
Business Overview	147
Products	147
ST. JUDE MEDICAL, INC.	147
Business Overview	148
Products	148
HOUSING OPTIONS	148
ASSISTED LIVING CONCEPTS, LLC	148
Business Overview	148
Products	148
BROOKDALE SENIOR LIVING	148
Business Overview	149
Products	149
CAPITAL SENIOR LIVING CORP.	149
Business Overview	149
Products	149
EMERITUS CORP.	149
Business Overview	150
Products	150
FIVE STAR QUALITY CARE, INC.	150
Business Overview	150
Products	150
LIFE CARE CENTERS OF AMERICA	150
Business Overview	150
Products	150
LIVHOME, INC.	151
Business Overview	151
Products	151
HCR MANOR CARE	151
Business Overview	151
Products	151
SUNRISE SENIOR LIVING, INC.	151
Business Overview	152
Products	152
ASSISTIVE DEVICES	152
A&D MEDICAL/LIFESOURCE	152
Business Overview	152

TOPIC	PAGE NO.
Products	152
ALIMED INC.	152
Business Overview	152
Products	153
ALLIED HEALTHCARE PRODUCTS, INC.	153
Business Overview	153
Products	153
AMERICAN MEDICAL ALERT CORP.	153
Business Overview	153
Products	153
ANALOGIC INC.	154
Business Overview	154
Products	154
BAXTER INTERNATIONAL, INC.	154
Business Overview	154
Products	154
BAYER AG (MILES-BAYER)	155
Business Overview	155
Products	155
BLUE CHIP MEDICAL PRODUCTS	155
Business Overview	155
Products	155
BRUNO INDEPENDENT LIVING AIDS INC.	155
Business Overview	156
Products	156
CARD GUARD AG	156
Business Overview	156
Products	156
CARETRENDS	156
Business Overview	156
Products	157
COBOLT SYSTEMS LTD.	157
Business Overview	157
Products	157
DOLPHIN COMPUTER ACCESS LTD.	157
Business Overview	157
Products	158
DUXBURY SYSTEMS INC.	158
Business Overview	158
Products	158
ECHO THERAPEUTICS	158
Business Overview	158
Products	158
EXACT DYNAMICS B.V.	159
Business Overview	159
Products	159
FREEDOM SCIENTIFIC INC.	159

TOPIC	PAGE NO.
Business Overview	159
Products	159
FRESENIUS MEDICAL CARE AG & CO. KGAA	160
Business Overview	160
Products	160
GRAHAM-FIELD HEALTH PRODUCTS	160
Business Overview	160
Products	160
GW MICRO INC.	160
Business Overview	161
Products	161
HEALTH FRONTIER, INC.	161
Business Overview	161
Products	161
HONEYWELL HOMMED	161
Business Overview	161
Products	162
HUMANWARE	162
Business Overview	162
Products	162
INCLINATOR COMPANY OF AMERICA	162
Business Overview	162
Products	162
INVACARE CORP.	163
Business Overview	163
Products	163
JOHNSON & JOHNSON	163
Business Overview	163
Products	163
KIMBERLY CLARK	163
Business Overview	164
Products	164
KROWN MANUFACTURING	164
Business Overview	164
Products	164
LIFE ALERT EMERGENCY RESPONSE	164
Business Overview	164
Products	164
LIFE GUARDIAN LLC	165
Business Overview	165
Products	165
LIFESCAN, INC.	165
Business Overview	165
Products	165
LIFTAVATOR INC.	165
Business Overview	166
Products	166

TOPIC	PAGE NO.
MEDLINE INDUSTRIES INC.	166
Business Overview	166
Products	166
MEDTRONIC MINIMED	166
Business Overview	166
Products	166
NIPRO DIAGNOSTICS INC.	167
Business Overview	167
Products	167
NXSTAGE MEDICAL, INC.	167
Business Overview	167
Products	167
OBS MEDICAL	167
Business Overview	168
Products	168
OMRON HEALTHCARE, INC.	168
Business Overview	168
Products	168
OPTELEC	168
Business Overview	169
Products	169
OTTO BOCK HEALTHCARE GMBH	169
Business Overview	169
Products	169
PARI PHARMA	169
Business Overview	169
Products	170
PHILIPS LIFELINE SYSTEMS INC.	170
Business Overview	170
Products	170
PRIDE MOBILITY PRODUCTS CORP.	170
Business Overview	170
Products	170
PULSE METRIC INC.	171
Business Overview	171
Products	171
RESMED, INC.	171
Business Overview	171
Products	171
ROCHE DIAGNOSTICS	171
Business Overview	172
Products	172
SAVARIA CORP.	172
Business Overview	172
Products	172
SCOTTCARE CORP.	172
Business Overview	172

TOPIC	PAGE NO.
Products	173
SIEMENS HEARING INSTRUMENTS INC.	173
Business Overview	173
Products	173
STARKEY LABORATORIES	173
Business Overview	173
Products	173
SUNRISE MEDICAL INC.	174
Business Overview	174
Products	174
SVENSKA CELLULOSA AKTIEBOLAGET SCA	174
Business Overview	174
Products	174
THORNDIKE PRESS	174
Business Overview	175
Products	175
THYSSENKRUPP ACCESS	175
Business Overview	175
Products	175
TYCO INTERNATIONAL	175
Business Overview	175
Products	175
WIDEX	176
Business Overview	176
Products	176
REHABILITATION	176
DJO GLOBAL, INC.	176
Business Overview	176
Products	176
KINDRED HEALTHCARE	177
Business Overview	177
Products	177
CHAPTER 9 GLOSSARY	179
ACTIVITIES OF DAILY LIVING (ADLS)	179
ALZHEIMER'S DISEASE	179
ARTHRITIS	179
ASSISTED LIVING	179
ASSISTIVE TECHNOLOGY	179
BABY BOOMER	180
CARDIOVASCULAR DISEASE	180
CAREGIVERS	180
CONGESTIVE OBSTRUCTIVE PULMONARY DISEASE (COPD)	180
DEMENTIA	180
DIABETES	180
DURABLE MEDICAL EQUIPMENT	181
ELDER/SENIOR	181

TOPIC	PAGE NO.
GERONTOLOGY	181
HOSPICE CARE	181
INSTRUMENTAL ACTIVITIES OF DAILY LIVING (IADL)	181
LONG-TERM CARE	181
PROSTHETICS AND ORTHOTICS	181

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE PROJECTED NEEDS OF THE U.S. ELDERLY, THROUGH 2018 (\$ MILLIONS)	8
TABLE 1 PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES, 2012 (MILLIONS/%)	15
TABLE 2 ELDERLY POPULATIONS COMPARED WITH OVERALL POPULATIONS BY STATE, 2009	16
TABLE 3 U.S. ELDERLY POPULATION, BY STATE, AS A PERCENTAGE OF THE OVERALL STATE POPULATION, 2010 (%)	18
TABLE 4 PROJECTED U.S. MARKET FOR ELDERCARE HEALTHCARE MEDICATIONS, PRODUCTS AND SURGICAL PROCEDURES, THROUGH 2018 (\$ MILLIONS)	28
TABLE 5 NUMBER OF DISCHARGES FROM NONFEDERAL U.S. HOSPITALS FOR INDIVIDUALS 65 OR OLDER, 2010 (THOUSANDS)	28
TABLE 6 PROJECTED U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	33
TABLE 7 SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME AND MANUFACTURER	35
TABLE 8 U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS AND SURGERY, THROUGH 2018 (\$ MILLIONS)	38
TABLE 9 PROJECTED U.S. MARKET FOR CARDIOVASCULAR DRUGS AND SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	38
TABLE 10 LEADING CANCER DRUGS, WITH PRODUCT, MANUFACTURER AND INDICATION, 2012	41
TABLE 11 PROJECTED U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH 2018 (\$ MILLIONS)	42
TABLE 12 PROJECTED MARKET FOR CANCER DRUGS FOR U.S. ELDERLY PATIENTS, THROUGH 2018 (\$ MILLIONS)	42
TABLE 13 PREVALENCE OF DIABETES IN THE U.S., THROUGH 2018 (CASES IN MILLIONS)	44
TABLE 14 SULFONYLUREAS	46
TABLE 15 ORAL HYPOGYCEMICS	48
TABLE 16 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND MONITORING PRODUCTS, THROUGH 2018 (\$ MILLIONS)	49
TABLE 17 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND MONITORING PRODUCTS FOR THE ELDERLY, THROUGH 2018 (\$ MILLIONS)	50
TABLE 18 PROJECTED U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS, SURGERY AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	50
TABLE 19 ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS OVER 40, 2010	52
TABLE 20 PROJECTED GLOBAL MARKET FOR PRODUCTS TO TREAT AMD, THROUGH 2018 (\$ MILLIONS)	53
TABLE 21 PROJECTED U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	53
TABLE 22 PROJECTED COSTS OF CATARACT SURGERY FOR THE U.S. ELDERLY, THROUGH 2018 (\$ MILLIONS)	54
TABLE 23 PROJECTED U.S. ELDERLY MARKET FOR GLAUCOMA PRESCRIPTION MEDICATIONS, THROUGH 2018 (\$ MILLIONS)	55
TABLE 24 PROJECTED U.S. EYEWEAR SALES, THROUGH 2018 (\$ MILLIONS)	56
TABLE 25 PROJECTED U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	56
TABLE 26 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS, THROUGH 2018 (\$ MILLIONS)	58

TABLE HEADING	PAGE NO.
TABLE 27 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS FOR THE ELDERLY, THROUGH 2018 (\$ MILLIONS)	58
TABLE 28 PROJECTED MARKET IN THE U.S. FOR DEMENTIA AND DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	59
TABLE 29 COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE, 2013	62
TABLE 30 PROJECTED MARKET IN THE U.S. FOR DEMENTIA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	63
TABLE 31 PROJECTED U.S. MARKET FOR DEPRESSION MEDICATIONS FOR THE ELDERLY, THROUGH 2018 (\$ MILLIONS)	65
TABLE 32 PROJECTED U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND SURGERIES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	66
TABLE 33 UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR OSTEOPOROSIS	66
TABLE 34 OSTEOPOROSIS MEDICATIONS BY TYPE	67
TABLE 35 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS, THROUGH 2018 (\$ MILLIONS)	68
TABLE 36 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	68
TABLE 37 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY, THROUGH 2018 (\$ MILLIONS)	69
TABLE 38 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	70
TABLE 39 PROJECTED U.S. MARKET FOR RESPIRATORY MEDICATIONS AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	71
TABLE 40 CURRENT ALLERGY TREATMENTS	73
TABLE 41 PROJECTED MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS IN THE U.S., THROUGH 2018 (\$ MILLIONS)	74
TABLE 42 PROJECTED U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	75
TABLE 43 PROJECTED U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	76
TABLE 44 PROJECTED U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	77
TABLE 45 CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S.	78
TABLE 46 PROJECTED U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY SUPPLIES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	80
TABLE 47 MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN 2008-2021	80
TABLE 48 PROJECTED U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	82
TABLE 49 SELECTED MEDICATIONS FOR BPH	82
TABLE 50 PROJECTED U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	83
TABLE 51 PROJECTED U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	88
TABLE 52 PROJECTED U.S. MARKET FOR HOME REMODELING FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	89
TABLE 53 PROJECTED U.S. MARKET FOR HOME HEALTH SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	89
TABLE 54 PROJECTED U.S. MARKET FOR ADULT DAY CARE SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	91

TABLE HEADING	PAGE NO.
TABLE 55 PROJECTED U.S. MARKET FOR SENIOR ASSISTED LIVING AND SKILLED NURSING FACILITIES FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	93
TABLE 56 TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2012	94
TABLE 57 TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2012	95
TABLE 58 TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2012	97
TABLE 59 SELECTED ACQUISITIONS AND MERGERS IN THE ELDERCARE MARKET, 2011 TO 2013 (\$ MILLIONS)	104
TABLE 60 PROJECTED U.S. ASSISTIVE TECHNOLOGY MARKET FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	106
TABLE 61 SELECTED MEDICAL/PERSONAL MONITORING AID MANUFACTURERS	109
TABLE 62 PROJECTED U.S. SALES OF MEDICAL/PERSONAL MONITORING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	110
TABLE 63 ACCESS AIDS MANUFACTURERS	112
TABLE 64 SELECTED MANUFACTURERS OF DAILY LIVING AIDS	113
TABLE 65 PROJECTED MARKET FOR DAILY LIVING AIDS FOR SENIORS, THROUGH 2018 (\$ MILLIONS)	113
TABLE 66 PROJECTED U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	114
TABLE 67 WHEELCHAIR MANUFACTURERS	115
TABLE 68 SCOOTER MANUFACTURERS	116
TABLE 69 PROJECTED U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	117
TABLE 70 AMBULATORY AID MANUFACTURERS	117
TABLE 71 PROJECTED U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	118
TABLE 72 VEHICLE ASSESS CONVERSION KIT MANUFACTURERS	118
TABLE 73 PROJECTED U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	119
TABLE 74 PROJECTED U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65, THROUGH 2018 (\$ MILLIONS)	119
TABLE 75 PROJECTED U.S. ELDERLY MARKET FOR COMMUNICATION AIDS, THROUGH 2018 (\$ MILLIONS)	120
TABLE 76 MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS, 2012	124
TABLE 77 MAJOR PRODUCT PIPELINES FOR BREAST CANCER	125
TABLE 78 MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER	126
TABLE 79 MAJOR PRODUCT PIPELINES FOR DIABETES	126
TABLE 80 MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE	128
TABLE 81 MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE	128
TABLE 82 MAJOR PRODUCT PIPELINES FOR OSTEOARTHRITIS	129
TABLE 83 MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS	129
TABLE 84 MAJOR PRODUCT PIPELINES FOR PAIN	130
TABLE 85 MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS	131
TABLE 86 MAJOR PRODUCT PIPELINES FOR DEPRESSION	132
TABLE 87 MAJOR PRODUCT PIPELINE FOR DEMENTIA PHARMACEUTICALS	133
TABLE 88 MAJOR PRODUCT PIPELINES FOR ASTHMA	133
TABLE 89 MAJOR PRODUCT PIPELINES FOR COPD	134

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE PROJECTED NEEDS OF THE ELDERLY BY TYPE OF NEED, 2013 AND 2018 (%)	9
FIGURE 1 U.S. POPULATION OVER 65 BY RACE, 2010 (%)	20
FIGURE 2 FUTURE BURDEN OF ARTHRITIS FOR THOSE OVER 65 IN THE U.S. BY GENDER, 2010-2030 (\$ MILLIONS)	31
FIGURE 3 ESTIMATED NEW CASES OF CANCER, GLOBALLY, 2008 (%)	39
FIGURE 4 CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%)	60
FIGURE 5 MARKET LEADERS FOR RECONSTRUCTIVE IMPLANT PRODUCTS (%)	70
FIGURE 6 PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER 65 (%)	86
FIGURE 7 PERCENT RANKING OF ASSISTED LIVING PROVIDERS BY CAPACITY IN THE U.S., 2012 (%)	94
FIGURE 8 PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN THE U.S., 2012 (%)	96
FIGURE 9 PROJECTED U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS OVER 65, 2013 AND 2018 (%)	107